Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 17/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 17/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | TPO | P07202 | 1/20 | 0.31 |
| ▸ | EPX | P11678 | 1/20 | 0.31 |
| ▸ | LPO | P22079 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769276 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNA4CYP2D6CHRNB4CHRNA3 | |
| SCHEMBL14776787 | 0.77 | CHRNB2 (0.52) | CHRNB2CHRNA4CYP2D6CHRNB4CHRNA3 | |
| SCHEMBL27211391 | 0.75 | NOS3 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3MPO | |
| SCHEMBL30473736 | 0.75 | NOS3 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3MPO | |
| SCHEMBL1769225 | 0.71 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3MPO | |
| SCHEMBL1000603 | 0.71 | NOS3 (0.46) | MPOTPOEPXLPO | |
| Hydrochloric Acid SCHEMBL710140 | 0.69 | NOS3 (0.45) | CYP2D6MPOTPOEPXLPO | |
| SCHEMBL1769429 | 0.69 | CHRNB2 (0.72) | CHRNB2CHRNA4CYP2D6CHRNB4CHRNA3 | |
| SCHEMBL13075015 | 0.64 | MCHR1 (0.45) | MPOTPOEPXLPO | |
| SCHEMBL7406955 | 0.64 | CHRNB2 (0.39) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513085-B1 | BICYCLIC COMPOUNDS AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2016-09-28 | — | — | EP | claimed |
| US-8735423-B2 | Bicyclic compounds as α4β2 nicotinic acetylcholine receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-05-27 | — | — | US | claimed |
| US-20130072518-A1 | BICYCLIC COMPOUNDS AS alpha4 beta2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Suven Life Science Limited (IN) | 2013-03-21 | — | — | US | claimed |
| EP-2513085-A1 | BICYCLIC COMPOUNDS AS alpha4beta2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2012-10-24 | — | — | EP | claimed |
| WO-2011061751-A1 | BICYCLIC COMPOUNDS AS α4β2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-05-26 | — | — | WO | claimed |
| EP-2513085-B1 | BICYCLIC COMPOUNDS AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2016-09-28 | — | — | EP | disclosed |
| US-8735423-B2 | Bicyclic compounds as α4β2 nicotinic acetylcholine receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-05-27 | — | — | US | disclosed |
| US-20130072518-A1 | BICYCLIC COMPOUNDS AS alpha4 beta2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Suven Life Science Limited (IN) | 2013-03-21 | — | — | US | disclosed |
| EP-2513085-A1 | BICYCLIC COMPOUNDS AS alpha4beta2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011061751-A1 | BICYCLIC COMPOUNDS AS α4β2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072518-A1 | BICYCLIC COMPOUNDS AS alpha4 beta2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA4, CHRNB4, CHRNA2 | CHRNB2 7/4885CHRNA4 1/4885CYP2D6 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.